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ABSTRACT
Creatine (Cr) Supplementation has been efficient and safely used as a therapeutic aid in many 
health and sickness conditions including muscle weakness, atrophy and metabolic disturbances. 
In Peripheral arterial obstructive disease (PAOD), chronic ischemia leads to muscle fiber atrophy 
and denervation, negative muscle metabolism alterations, thus reducing strength and endurance, 
impairing general physical fitness. Adding the studied benefits of Cr supplementation and the 
clinical frame of PAOD, it presents Cr Supplementation as a potential therapeutic aid to be 
considered. Objective: To make a systematic review in scientific literature, searching for studies 
involving Cr supplementation in PAOD individuals. Method: A search for Portuguese and English 
written articles, published over the last ten years, including terms related to PAOD and Cr 
supplementation, was conducted on PubMed SciELO, and LILACS. Results: Only one study evaluated 
the influence of Cr supplementation in the desired sample (PAOD), describing positive effects in 
walking distance and blood properties. Due to lack of scientific data, the use Cr supplementation 
in PAOD population, including metabolic, functional and structural considerations was discussed. 
Conclusion: Despite the presented discussion for using Cr supplementation in PAOD as a potential 
therapeutic aid, only one previous study could verify its benefits. Therefore, it still has a gap in 
scientific literature, leaving several possibilities for future studies researching for possible benefits 
to counteract the loss of functional fitness and impairments in musculoskeletal structure and 
metabolism of diseased individuals.
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Suplementação de creatina como potencial agente terapêutico 
na reabilitação da doença arterial obstrutiva periférica
RESUMO
Suplementação de Creatina (Cr) têm sido utilizada de forma segura e eficaz em diversas condições 
de saúde e doença, incluindo fraqueza, atrofia e distúrbios metabólicos musculares. Na Doença 
arterial obstrutiva periférica (DAOP), a isquemia crônica promove atrofia, denervação e prejuízos 
metabólicos musculares, reduzindo a força e resistência, prejudicando a aptidão física geral. 
Tomando em conjunto, os benefícios conhecidos da suplementação de Cr e a apresentação 
clínica da DAOP, apresentam a suplementação de Cr como potencial agente terapêutico a ser 
considerado. Objetivo: Realizar uma revisão sistemática da literatura científica procurando por 
estudos envolvendo a suplementação de Cr em portadores de DAOP, publicados nos últimos dez 
anos. Método: Uma pesquisa por artigos escritos em português e inglês no período descrito, 
incluindo o cruzamento de termos relacionados a DAOP e a suplementação de Cr foi realizada no 
PubMed, SciELO, e LILACS. Resultados: Um único estudo avaliou a influência da suplementação 
de Cr na amostra desejada (DAOP), descrevendo efeitos positivos na distância de caminhada e em 
propriedades sanguíneas. Devido à escassez de dados sobre o tema, o potencial uso da Cr na DAOP 
incluindo considerações metabólicas, funcionais e estruturais foi discutido. Conclusão: Apesar das 
apresentadas considerações para a utilização da Cr como potencial agente terapêutico na DAOP, 
apenas um estudo prévio verificou benefícios. Assim ainda há uma grande lacuna na literatura 
científica, deixando campo aberto para futuros estudos na procura de possíveis benefícios no 
combate a perda funcional, prejuízo da estrutura e metabolismo muscular de indivíduos doentes.
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INTRODUCTION
Over the last two decades an increasing 
of evidences identified the nutritional 
supplement creatine (Cr) as the most effective 
ergogenic aid to improve exercise tolerance, 
muscle strength and lean body mass.1,2
The undeniable documented benefits 
associated with an excellent safety profile of its 
use, lead researches to explore Cr as a therapeutic 
aid in many health and sickness conditions,3 as 
recent reviewed by Gualano et al.4,5
In this context, Cr supplementation can 
possibly counteract the final result of many 
degenerative diseases, like muscle weakness, 
atrophy and metabolic disturbances.4,5
In peripheral arterial obstructive disease 
(PAOD), the chronic obstruction in blood flow to 
distal territories due to atherosclerotic process, 
and its consequence and constant mismatch 
between oxygen delivery and demand, lead to 
a progressive disability cycle involving muscle 
fiber atrophy and denervation, negative muscle 
metabolism alterations, reduced strength and 
endurance, impairing general physical fitness 
capacity, specially walking capacity, in diseased 
individuals.6-9
Cost-effectiveness strategies10 to counteract 
muscle, nerve and metabolism impairments, and 
to reduce the loss of physical fitness capacity, 
like exercise training have been previously 
proposed11,12 and studied.13-17
Therefore, adding up the cost-effective-
ness and the safety profile of studied benefits 
of Cr supplementation18,19 and the clinical 
frame of PAOD, the use of Cr rises as a poten-
tial therapeutic aid to be considered.
OBJECTIVE
So, the goal of this study was to make a 
systematic review in scientific literature, sear-
ching for studies involving Cr supplementation in 
PAOD individuals, published in the last ten years.
METHOD
A search in the last ten years for Portu-
guese and English written articles including 
and incluiding terms related to PAOD and Cr 
supplementation was conducted on PubMed, 
SciELO, and LILACS.
Included terms: 1) PAOD: a) English - Periphe-
ral Arterial Disease and Intermittent Claudication; 
b) Portuguese - Doença Arterial Periférica, Obstru-
ção Arterial Periférica e Claudicação Intermittente. 
2) Cr Supplementation: a) English - Creatine, 
Creatine Monohydrate and Creatine Supplemen-
tation; b) Portuguese - Creatina, Creatina Mono-
hidratada, Suplementação de Creatina.
All included terms found in the articles 
were individually selected by the title and 
abstract to be included in this review. After 
the selection, the articles were taken from two 
open access libraries (University of São Paulo 
and Federal University of São Paulo).
RESULTS
After our research, only on Pubmed, 
articles related to the subject were found. 
Relevant studies (3 studies) were selected 
after matching “Intermittent Claudication x 
Creatine” (29 searched, 3 selected), and from 
“Peripheral Arterial Disease x Creatine” (85 
searched, 13 selected).
Studies were excluded if they were not 
about investigations concerning the subject 
(ie. Creatine supplementation, or peripheral 
arterial disease). Articles that scope periphe-
ral arterial disease metabolism, including 
ATP-PCr, were selected, even if they were not 
specific, and they were mentioned along this 
study.
One important detail to point out is that 
the previous period planned (last ten years) 
was extended to 15 years due to limited data.
Only one study20 from Cardiology Center 
of Moscow (Russia), in fact, evaluated the in-
fluence of Cr supplementation in the desired 
sample (PAOD), describing positive influen-
ce not only in maximal walking distance, 
but as well as on platelet aggregation, blood 
rheology, coagulation and fibrinolytic system.
DISCUSSION
Despite the presented discussion of Cr 
supplementation as a potential therapeutic 
aid in PAOD population, we could only find one 
study published in 1994 from Russian resear-
chers. Panchenko et al.20 studied the influence 
of daily 10g supplementation of Cr in 37 PAOD 
patients, versus non-diseased paired sample 
men, with symptoms of intermittent claudi-
cation, with diagnosis confirmed by angio-
graphy or ultrasound technique. Comparing 
patients with control group (before and after 
this intervention), the diseased supplemented 
group significantly increased maximal walking 
distance. The authors attributed this improve-
ment on walking due to positive influences on 
platelet aggregation, blood rheology, coagula-
tion and fibrinolytic system.20
Surprisingly, the described method in 
the present research, no other studies were 
conducted until now (confirming or refuting the 
results), despite the clinical benefits observed 
and documented in the PAOD population of 
Panchenko et al.20 study.
Due the lack of scientific data evaluating 
this subject, we believe it will be interesting 
to better discuss the potential use of Cr 
supplementation in PAOD population, 
including metabolic, functional and structural 
considerations:
Metabolic
In PAOD, due to chronic atherosclerotic 
process, the reduced blood flow leads to im-
paired oxygen delivery in peripheral territories 
distal to obstruction6. Therefore, every time 
the peripheral demand to oxygen increases, 
for example during repeated muscular con-
tractions (eg. Walking), there is a mismatch 
between delivery and demand of oxygen, 
increasing the dependence of anaerobic 
energy supply, leading to increase in local 
acidosis and consequent fatigue.21-24
The peripheral metabolic fatigue can be 
observed clinically by ischemia symptoms (in-
termittent claudication), commonly described 
as pain while walking, that prevented the pa-
tient to continue.6 Moreover, not only in the 
acute increase of demand of oxygen by active 
muscles (eg walking),23,24 evidence suggests 
that this chronic ischemic process leads to 
more permanent decreases in energy storages 
(ATP-PCr, glycogen, lipids), reduced glycolitic 
and oxidative enzymes, and decreased mito-
chondrial function.21-24 Adding up, the cited 
alterations impairs ATP synthesis and rege-
neration. In fact, previous studies using Phos-
phorus-31 magnetic resonance spectroscopy 
found a perturbation in oxidative ATP synthe-
sis rate and a delayed PCr recovery time in 
PAOD patients.21-23 PCr recovery time was the 
strongest inversely correlated factor together 
with walking capacity,22 and predictor of late 
follow up requirements for surgical limb inter-
ventions and mortality.23 One can argue that 
once blood flow can be restored (eg angio-
plasty, revascularization surgery), the meta-
bolic impairments could reverse, but Pipinos 
et al.25 could not find improvement of clinical 
performance after surgical procedure, sugges-
ting that blood flow restriction is not the only 
factor implying in walking impairment in PAOD 
patients.
Wolosker et al.26 found a very low pre-
dictive value of the ankle-brachial index in 
the evaluation of walking capacity in patients 
with intermittent claudication. According to 
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it, many exercise intervention studies could 
document significant gain in many spheres of 
physical fitness without a significant improve-
ment in blood flow, confirming the data about 
an important metabolic contribution leading 
to function.15-17
Even in non diseased (normal blood flow) 
persons (eg athletes), an increase on metabo-
lic function is capable to improve performan-
ce, as seen in studies with Cr supplementa-
tion, corroborating the data.27,28 The ingestion 
of 20g/day of Cr for 5 days can lead to increase 
more than 20% of muscle Cr content, of whi-
ch approximately 20% can be attributable to 
PCr form.1 As reviewed previously by Rawson 
and Persky27 (2007), in the context of exerci-
se performance, Cr supplementation can act 
as an ergogenic aid through some mechanis-
ms, mainly: a) increased storages of glycogen 
and PCr pre-exercise; b) reduced time to PCr 
resynthesys; c) reduced post exercise mus-
cle damage and inflammation; d) increased 
training intensity, volume, and sensitivity of 
contractile muscle fibers to Ca++; e) acts in 
oxidative stress prevention via direct and in-
direct antioxidant action; f) maintains the ATP/
ADP ratio and maintains cellular pH via H+ bu-
ffering; and g) provide activation of glycolysis 
and glycogenolysis through Pi release thereby 
integrating the carbohydrate and Cr degrada-
tion to provide energy at the early stage of 
exercises.
Finally, due to metabolic alteration 
seen in PAOD and the Cr supplementation 
benefits mapped until now, there is a large 
and extensive field of possibilities for original 
researches, until this moment only one study 
was done.20 With a plausible application of this 
nutritional supplement (based on clinical rea-
soning), Creatine can act as a therapeutic aid 
aiming to restore the metabolic impairments 
of PAOD.
Functional
Performance in daily living regarding 
general physical efforts, with special consi-
deration to walking capacity, is impaired in 
PAOD individuals.6 The worsening of arterial 
obstruction and consequent disease evolutio-
nal stage was previously correlated with these 
impairments.14,15,29 In fact, studies made with 
ambulatory measurements and subjective 
questionnaires to analyze physical function, 
observed decreasing levels of physical activity 
in more severe diseased patients.14,15,29,30
This scenario of reduced physical capacity 
due to PAOD, increases the levels of a more 
sedentary lifestyle, which provokes in end 
a “progressive disability cycle” of physical 
function.31 In this field, scientific literature 
has been previously documented reduced 
values of strength, power and endurance in 
patients when compared with non diseased 
controls.7-9,16,17,30,32-34
Once muscular strength could be strongly 
correlated with walking capacity (most 
accessed measure of fitness capacity) in PAOD 
patients by Regensteiner et al.34 and Gerdle 
et al.32 interventions (resistance training) to 
counteract this condition has been propo-
sed11,12 and studied with documented positive 
benefits.13-17
Additional to resistance training, as 
a beneficial exercise type prescription in 
non diseased population,35 association of 
Cr supplementation has been studied and 
proposed as a more effective intervention to 
improvements muscular strength.36 In fact two 
recent meta-analysis37,38 documented that Cr 
supplementation can significantly increase 
muscular capacity to generate strength.
In this context, despite of documented 
positive benefits, there is still a gap in actual 
knowledge about if Cr supplementation can 
increase strength per se or due to consequent 
positive adaptations in training capacity, 
but this discussion is beyond of scope of 
our present considerations and has been 
fashionably reviewed before by Lemon et al.39 
and Gualano et al.40
To our knowledge, no previous studies 
including strength training in combination with 
Cr supplementation was conducted yet in PAOD 
patients, leaving a large, open and a potential 
attractive field to original investigations.
Structural
Significant morphological changes in 
skeletal muscle are presented by PAOD 
patients, including atrophy (sarcopenia), 
modification in the patterns of fiber type 
distribution, disturbance in neural function, 
and these changes have been associated with 
impaired walking capacity.34,41-43
Askew et al.42 and Regensteiner et al.34 
using muscular biopsy, found a reduction in 
skeletal muscle cross sectional area, and a 
reduction in size of fibers type I and IIa, com-
paring PAOD patients with their paired healthy 
controls.
Mc Guigan et al.41 documented a signi-
ficant increase in muscular capillary density 
due the chronic ischemic process, and also an 
increase in expression of myosin heavy chain 
(MHC) IIx, besides a reduction in MHC I. As 
mentioned before,34,42 this study also verified 
a reduction in cross sectional area of fibers 
type I and IIa.
Mc Dermott et al.43 showed a reduction 
in neural function, due to impairments in 
motoneuron, as measured by a reduction in 
nerve conduction velocity presented in elec-
troneuromyography of 109 older Italian com-
munity-dwelling PAOD patients.
Gualano et al.44 conducted a recent review 
about positive influence of Cr supplementa-
tion in enhancement of muscular hypertrophy 
and strength in healthy persons. The author’s 
conclusion was a suggestion that the gains ob-
tained was not due water retention, but gene 
expression and protein translation efficiency 
related to hypertrophy, and proliferation and 
activation of satellite cels.
Again, a beneficial combination of resis-
tance training and Cr supplementation is capa-
ble to benefit patients with neuropathies45 and 
several other nervous system conditions.46-48
In conclusion Cr supplementation can act 
as a main potential counter-actor of degenera-
tive muscle and nervous impairments conse-
quent to chronic PAOD, but unfortunately no 
studies were conducted before to corroborate 
or refute our present hypothesis.
Other Considerations
Taking into account, that the prevalence of 
PAOD increases with age,49-51 is important to 
consider that the impairments exclusively due 
to disease occurs, most of the time, associated 
with the loss of physical function of normal 
sedentary aging process.52-56 It is reasonable 
to conclude that the morphological and me-
tabolic changes in skeletal muscle, as well 
as reduction in physical fitness derived from 
normal aging, can be empowered in PAOD 
patients.41-43 Dalbo et al.57 recently published 
a detailed manuscript about the benefits of 
Cr supplementation in promoting beneficial 
effects on many aspects of physical fitness loss 
due to aging.
Comorbidities as dyslipidemia, diabetes 
mellitus, chronic kidney disease, hypertension, 
pro-inflammatory status, cardiac dysfunctions 
(e.g. hearth failure), chronic obstructive pul-
monary disease (due to high smoke prevalen-
ce) are frequently presented in the diseased 
pacients.6
As presented by Gualano et al.4,5 Cr 
supplementation have already been studied 
showing benefits undoing some of the 
unfavorable changes for the majority of those 
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comorbidities. In the end, Cr monohydrate has 
been the most studied supplement applied on 
sports performance enhancement and several 
health conditions.4,5,58
CONCLUSION
Despite the presented discussion of Cr su-
pplementation in PAOD patients as a potential 
therapeutic aid, to our knowledge, only one 
previous study could verify its benefits. The-
re is a large and extensive field of possibilities 
for future studies, which are encouraged by 
the authors. These surveys should focus on 
the possible benefits to counteract the loss of 
functional fitness and impairments in muscu-
loskeletal structure and metabolism of aging 
diseased individuals.
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